

HEART FAILURE UPDATE 2018



Canadian Heart Failure Society
Société canadienne d'insuffisance cardiaque

Co-presented by: _____



TORONTO, MAY 11-12

Metro Toronto Convention Centre

South Building, 222 Bremner Boulevard, Level 700

For registration, symposia and congress details, visit:

HFupdate.ca

About Heart Failure Update 2018

The Canadian Heart Failure Society and the Ted Rogers Centre for Heart Research are pleased to again host Canada's largest meeting devoted to heart failure. With a dual lens of clinical care and novel research, this compelling event has a unique bench-to-bedside makeup. Interactive sessions feature a roster of expert plenaries, panel discussions, workshops, and scientific sessions with a focus on improved heart failure treatment and prevention. Faculty includes an array of both national and international heart failure key opinion leaders. We hope you can join us this May in Toronto!

Who should attend:

Healthcare and research professionals involved in heart failure care:

- Cardiologists and Internal Medicine Specialists (community & academic)
- Nurses, Nurse Practitioners and Allied Health Members
- Residents & Fellows
- Investigators, Research Staff & Trainees

PLANNING COMMITTEE CHAIRS

JONATHAN HOWLETT

MD, FRCPC, FACC

Past President

Canadian Heart Failure Society

MANSOOR HUSAIN

MD, FRCPC

Executive Director

Ted Rogers Centre for Heart Research

SERGE LEPAGE

MD, FRCPC, CSPQ

Past President

Quebec Heart Failure Society

FRIDAY, MAY 11

7:30 a.m. Breakfast Buffet and Registration

JOINT PLENARY: PRECISION MEDICINE: PATIENT, POPULATION, OR BOTH?

Co-Chairs: Jonathan Howlett, MD | Mansoor Husain, MD

8:30 a.m. Welcome and introduction Jonathan Howlett, MD

8:35 a.m. Can macrodata predict response to therapy? Larry Allen, MD

8:55 a.m. Genes to genomes: Evolution of molecular testing for inherited cardiomyopathy Birgit Funke, PhD

9:15 a.m. The journey of the biomarker from bench to bedside Douglas Lee, MD

9:35 a.m. Plenary Q&A

9:50 a.m. Flash science trainee presentations

10:00 – 10:25 a.m. Break

CHFS CLINICAL WORKSHOPS I

TED ROGERS CENTRE SCIENTIFIC SESSION: HOW TO ENGINEER A HEART
Chair: Craig Simmons, PhD

Choose one to attend:

Featured presentations and Q&A:

10:25 – 11:40 a.m. I. CCS comprehensive HF guidelines – Michael McDonald, MD – Eileen O'Meara, MD

Biomaterials that improve heart function – Ren-Ke Li, MD

II. Ms. Understood: Gender-based differences and HF therapies: Drugs, devices and surgery
Vivek Rao, MD – Shelley Zieroth, MD

The genomic blueprint of the heart – Benoit Bruneau, MD

III. What patient advocacy means in 2018 – Sean Virani, MD

Importance of vasculature to heart regeneration – Sara Vasconcelos, PhD

11:40 a.m. Lunch Buffet Opens

12:05 – 1:20 p.m. Lunch Symposium

JOINT PLENARY: EVOLVING CONCEPTS IN HEART FAILURE

Co-Chairs: Carolina Alba, MD | Michael Farkouh, MD

1:35 p.m. Amlodipine therapy for iron-overload cardiomyopathy: The enduring value of translational research Gavin Oudit, MD

1:55 p.m. Heart failure with and without atrial fibrillation: Are they different diseases? Martin Cowie, MD

2:15 p.m. Update on ischemic conditioning: Bench to bedside opportunities for clinical translation Nicolas Noiseux, MD

2:35 p.m. Plenary Q&A

2:50 p.m. Flash science trainee presentations

3:00 – 3:20 p.m. Break

CHFS CLINICAL WORKSHOPS II

TED ROGERS CENTRE SCIENTIFIC SESSION: CARDIAC SIGNALLING & METABOLISM
Chair: Sara Vasconcelos, PhD

Choose one to attend:

Featured presentations and Q&A:

3:20 – 4:35 p.m. I. Bridging the gap between clinical medicine and basic science: Opening Pandora's box
Phyllis Billia, MD – Anthony Gramolini, PhD

Can modulating cardiac metabolism prevent HF? – Mansoor Husain, MD

II. Nursing: Managing goals of care – Leah Steinberg, MD – Pat Strachan, RN, PhD

HDL and cell signaling in the heart: Roles in cardioprotection – Bernardo Trigatti, PhD

III. Cardiorenal disease – Nadia Giannetti, MD

Apelin analogues as novel therapies for cardiovascular disease – Gavin Oudit, MD

4:35 p.m. End of Daily Program

SATURDAY, MAY 12

7:30 a.m.	<i>Breakfast Buffet</i>	
7:55 – 8:55 a.m.	Breakfast Symposium	
JOINT PLENARY: SWEET FAILURE: HFpEF AND DIABETES		Co-Chairs: Mansoor Husain, MD Eileen O'Meara, MD
9:05 a.m.	Opening remarks	Mansoor Husain, MD
9:10 a.m.	Targeting the diagnosis of HFpEF	Justin Ezekowitz, MB BCH
9:25 a.m.	New and emerging heart failure therapies: 2018 and beyond	John McMurray, MD
9:45 a.m.	Diabetic cardiomyopathy: Real or imagined?	Kim Connelly, MBBS, PhD
10:00 a.m.	Plenary Q&A	
10:15 a.m.	Flash science trainee presentations	
10:25-10:45 a.m.	<i>Break</i>	
10:45 – 12:00 p.m.	CHFS CLINICAL WORKSHOPS III	TED ROGERS CENTRE SCIENTIFIC SESSION: THE IMPORTANCE OF GENOMICS TO OUR UNDERSTANDING OF HEART DISEASE Chair: Seema Mital, MD
	<i>Choose one to attend:</i>	<i>Featured presentations and Q&A:</i>
	I. Nursing: Initiation & titration of HF medications – Karen Harkness, RN, PhD – Serge Lepage, MD	Genomic-guided therapies: Can we cure cardiomyopathy? – Carolyn Ho, MD
	II. Advanced HF therapies: When to refer patients – Stephanie Poon, MD	How deep learning can predict cardiac arrest – Anna Goldenberg, PhD
	III. Imaging tools for HF in 2018 – Carolina Alba, MD – Nowell Fine, MD	A novel biomarker for arrhythmogenic cardiomyopathy – Robert Hamilton, MD
12:00 p.m.	<i>Lunch Buffet Opens</i>	
12:25 – 1:40 p.m.	Lunch Symposium	
JOINT PLENARY: WHAT WE MUST KNOW ABOUT CARDIOTOXICITY		Co-Chairs: Serge Lepage, MD Dinesh Thavendiranathan, MD
1:55 p.m.	Why cardiologists must care about cancer immunotherapy	Javid Moslehi, MD
2:15 p.m.	Clonal hematopoiesis: A pathway to cancer, a pathway to heart disease	Aaron Schimmer, MD
2:35 p.m.	Novel diagnosis and treatment of cardiac amyloidosis: Can we cure the incurable?	Natalie Galant, PhD
2:55 p.m.	Plenary Q&A	
3:10 p.m.	Closing remarks	Serge Lepage, MD
3:10 – 4:00 p.m.	<i>Trainee Research Showcase & Reception</i>	



Following this program, participants will be able to:

- Approach and better manage the increasing problem of cardiotoxicity as it relates to heart failure
- Identify how recent advances in genetics will impact the referral and treatment of heart failure patients
- Describe the novel biomarker journey from bench to clinical care of heart failure
- Describe the unique interactions between diabetes and heart failure
- Discuss new and emerging concepts in heart failure with preserved ejection fraction

THANK YOU TO OUR SPONSORS!

This program was made possible through educational grants from the following sponsors and was planned to achieve scientific integrity, objectivity and balance.

CHIEF SCIENTIFIC SPONSOR



GOLD SPONSOR



PARTNER IN INNOVATION



SILVER PLUS SPONSOR



Cardiovascular

SILVER SPONSORS



Bayer



Bristol-Myers Squibb



Medtronic



Canadian Cardiovascular Society

Leadership. Knowledge. Community.

FOR MORE INFORMATION

Serena Chenoy at contact@HFupdate.ca or 514-935-1840

Jeff Jurmain at jeff.jurmain@tedrogersresearch.ca or 416-946-8305

This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, and approved by the Canadian Cardiovascular Society. You may claim a maximum of 9 hours.